Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations
Agreement accelerated by Caladrius’ initial investment in Cend
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations
Agreement accelerated by Caladrius’ initial investment in Cend
Read more at globenewswire.com